Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418501 | 0.78 | AXL (0.38) | MEN1KMT2AADRA2AADRA2CKDR | |
| SCHEMBL221242 | 0.76 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL29391624 | 0.76 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL10972199 | 0.76 | GOT1 (0.47) | — | |
| SCHEMBL8596239 | 0.74 | ADRA2A (0.58) | MEN1KMT2AMAPK10GFERAPAF1 | |
| SCHEMBL7748839 | 0.74 | MEN1 (0.50) | MEN1KMT2AMAPK10GFERAPAF1 | |
| SCHEMBL6574416 | 0.74 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL11133606 | 0.74 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL6175584 | 0.74 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A | |
| SCHEMBL4243882 | 0.74 | KMT2A (0.73) | MEN1KMT2AMAPK10GFERADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2712000-B1 | Materials for Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20160043332-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-20160043332-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-9024026-B2 | Copper (I) complexes for optoelectronic devices | CYNORA GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9024026-B2 | Copper (I) complexes for optoelectronic devices | CYNORA GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-8835021-B2 | Materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835021-B2 | Materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130299744-A1 | METAL COMPLEXES HAVING ADAPTABLE EMISSION COLORS FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130299744-A1 | METAL COMPLEXES HAVING ADAPTABLE EMISSION COLORS FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130150581-A1 | COPPER (I) COMPLEXES FOR OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2513057-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20110155954-A1 | Materials for Organic Electroluminescence Devices | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | US | disclosed |
| US-20110155954-A1 | Materials for Organic Electroluminescence Devices | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | US | disclosed |
| WO-2011072791-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| EP-1799218-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | Tibotec Pharmaceuticals Ltd. (IE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006035061-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160043332-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | SOD1, AOC1, NCS1 | MEN1 421/4885KMT2A 2329/4885MAPK10 802/4885 |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | MEN1 249/4885KMT2A 3201/4885MAPK10 333/4885 |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | MEN1 4876/4885KMT2A 3844/4885MAPK10 2996/4885 |
| US-20110155954-A1 | Materials for Organic Electroluminescence Devices | NCS1, L1CAM, CD274 | MEN1 449/4885KMT2A 2510/4885MAPK10 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.